High yield bond markets see issuance slow as borrowers and investors step back from new deals due to macroeconomic headwinds and geopolitical uncertainty
Elevated inflation and interest rate hikes in Europe and the US,...more
A rebound in European corporate transactions has driven a double-digit acceleration in leveraged finance earmarked for M&A (excl. buyouts), with a robust pipeline setting the stage for an active 2022.
In the summer of...more
2/22/2022
/ Acquisitions ,
Borrowers ,
Capital Markets ,
Coronavirus/COVID-19 ,
Corporate Governance ,
EU ,
Financial Services Industry ,
Global Dealmaking ,
High Yield Bonds ,
Investors ,
Lenders ,
Leveraged Finance ,
Leveraged Loans ,
Mergers ,
Shareholders ,
UK
Following a year of healthy activity, M&A deals in the pipeline are set to sustain leveraged finance issuance in the pharmaceutical, medical and biotech sector in the months ahead -
Lender appetite for exposure to the...more
2/9/2022
/ Acquisitions ,
Biotechnology ,
Borrowers ,
Capital Markets ,
Coronavirus/COVID-19 ,
Environmental Social & Governance (ESG) ,
Financial Services Industry ,
Global Market ,
Healthcare ,
High Yield Bonds ,
Lenders ,
Leveraged Loans ,
Mergers ,
Pharmaceutical Industry
A rebound in European corporate transactions has driven a double-digit acceleration in leveraged finance earmarked for M&A (excl. buyouts), with a robust pipeline setting the stage for an active 2022.
In the summer of...more
2/3/2022
/ Acquisitions ,
Borrowers ,
Capital Markets ,
EU ,
Financial Services Industry ,
High Yield Bonds ,
International Trade ,
Investors ,
Lenders ,
Leveraged Finance ,
Leveraged Loans ,
Mergers ,
Refinancing
After COVID-19 concerns brought issuance to a near halt in March, Q2 high yield bond activity climbed in most markets as borrowers sought to boost balance sheets and cash reserves.
In the first six months of 2020, high...more